Matching trials
1,853 results
- Brexpiprazole for the Long-term Treatment of Patients With Agitation Associated With Dementia of the Alzheimer’s Type: Complete Statistical AnalysisIndependent statistical analysis of Brexpiprazole for the Long-term Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- BRIGHT AML1019Independent statistical analysis of A Study Evaluating Intensive Chemotherapy With or Without Glasdegib or Azacitidine With or Without Glasdegib In Patients With Previously Untreated Acute Myeloid Leukemia: primary endpoint results, effect estimate…
- BROADWAYA detailed statistical analysis of the phase 3 BROADWAY trial evaluating obicetrapib on top of maximum tolerated lipid-modifying therapies in patients with dyslipidemias and high cardiovascular risk.
- BROOKLYNIndependent statistical analysis of Evaluate the Effect of Obicetrapib in Patients With HeFH on Top of Maximum Tolerated Lipid-Modifying Therapies.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- BTX-A-HAC NGIndependent statistical analysis of Efficacy and Safety of Clostridium Botulinum Toxin Type A to Improve Appearance of Moderate to Severe Glabellar Lines: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Buprenorphine Plus Baclofen to Increase Analgesia in Healthy Volunteers: Complete Statistical AnalysisIndependent statistical analysis of Buprenorphine Plus Baclofen to Increase Analgesia in Healthy Volunteers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04251819).
- BWSP3Independent statistical analysis of Black Widow Spider Antivenin for Patients With Systemic Latrodectism: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00657540).
- C-earlyIndependent statistical analysis of A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve…
- C1 Esterase Inhibitor (C1INH-nf) for the Treatment of Acute Hereditary Angioedema (HAE) Attacks: Complete Statistical AnalysisIndependent statistical analysis of C1 Esterase Inhibitor (C1INH-nf) for the Treatment of Acute Hereditary Angioedema (HAE) Attacks: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- C1 Esterase Inhibitor in Hereditary Angioedema (HAE)(Extension Study): Complete Statistical AnalysisIndependent statistical analysis of C1 Esterase Inhibitor in Hereditary Angioedema (HAE)(Extension Study): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00292981).
- C3POIndependent statistical analysis of Cerebral Perfusion Pressure Using Precedex and Other Sedatives: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01169467).
- CAIRO2Independent statistical analysis of CAIRO2, a randomized phase 3 trial of capecitabine, oxaliplatin and bevacizumab with or without cetuximab in advanced colorectal cancer. Covers trial design, endpoints, planned statistical methods, interpretation, and…
- CAIRO3Independent statistical analysis of the CAIRO3 phase 3 trial evaluating capecitabine plus bevacizumab maintenance treatment versus observation after induction in advanced colorectal carcinoma.
- CALGB 9633An independent statistical analysis of CALGB 9633, a randomized phase 3 trial of surgery with or without paclitaxel and carboplatin chemotherapy in patients with stage IB non-small cell lung cancer.
- CALIPSOIndependent statistical analysis of CALIPSO: Calfactant for Acute Lung Injury in Pediatric Stem Cell Transplant and Oncology Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- CAN-COVIDIndependent statistical analysis of CAN-COVID, a randomized phase 3 study of canakinumab versus placebo for cytokine release syndrome in participants with COVID-19-induced pneumonia, including its primary binary endpoint, logistic regression, odds ratio,…
- CANDLEIndependent statistical analysis of Phase 3 Study of Oral Ibrexafungerp (SCY-078) Vs. Placebo in Subjects With Recurrent Vulvovaginal Candidiasis (VVC): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Cannabidiol and Management of Endometriosis Pain: Complete Statistical AnalysisIndependent statistical analysis of Cannabidiol and Management of Endometriosis Pain: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04527003).
- CANOPY-2Independent statistical analysis of Phase III Study Evaluating Efficacy and Safety of Canakinumab in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancers as a Second or Third Line Therapy:…
- Canopy-AComplete statistical analysis of the phase 3 Canopy-A trial of canakinumab versus placebo as adjuvant therapy in completely resected non-small cell lung cancer, including disease-free survival, subgroup analyses, statistical methodology, safety, and…
- CANTOSAn independent statistical analysis of the phase 3 CANTOS trial (NCT01327846), comparing three canakinumab doses with placebo for first adjudicated major adverse cardiovascular events in 10066 participants with atherosclerosis, with hazard ratios,…
- CAO/ARO/AIO-04Independent statistical analysis of the randomized phase 3 CAO/ARO/AIO-04 trial of 5-fluorouracil and oxaliplatin versus 5-fluorouracil in rectal cancer, including trial design, disease-free survival methodology, endpoint definitions, and statistical interpretation.
- CAPACITYIndependent statistical analysis of Reducing the Burden of Chronic Psychotic Disorders in Tanzania (CAPACITY): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04327843).
- Caphosol Study: Prevention of Oral Mucositis in Children, Adolescents and Young Adults Receiving Chemotherapy: Complete Statistical AnalysisIndependent statistical analysis of Caphosol Study: Prevention of Oral Mucositis in Children, Adolescents and Young Adults Receiving Chemotherapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- CAPPSIndependent statistical analysis of Combined Antioxidant and Preeclampsia Prediction Studies (CAPPS): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00135707).
- CAPYBARAIndependent statistical analysis of A Study Evaluating the Effect of Filgotinib Dose De-escalation in Participants With Ulcerative Colitis (UC) in Remission: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- CARAVAGGIOIndependent statistical analysis of Apixaban for the Treatment of Venous Thromboembolism in Patients With Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Carboxyamidotriazole in Treating Patients With Stage III or Stage IV Non-small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Carboxyamidotriazole in Treating Patients With Stage III or Stage IV Non-small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- CARESComplete statistical analysis of the CARES phase 3 trial of febuxostat versus allopurinol in participants with gout and cardiovascular comorbidities, including MACE, cardiovascular death, myocardial infarction, stroke, and survival-analysis methodology.
- CARMENAAn independent statistical analysis of the CARMENA phase 3 trial evaluating nephrectomy and sunitinib alone in metastatic renal cell carcinoma, including design, endpoints, planned analysis, and statistical interpretation.
- CARVIVA-HFIndependent statistical analysis of Heart Rate Reduction in Heart Failure: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01178528).
- CASPIANIndependent statistical analysis of CASPIAN, the randomized phase 3 trial of durvalumab with platinum-based chemotherapy in untreated extensive-stage small cell lung cancer, including overall survival, progression-free survival, response, statistical methodology, and interpretation.
- CASSIOPEIAA complete statistical analysis of the phase 3 CASSIOPEIA trial evaluating daratumumab in transplant-eligible participants with previously untreated multiple myeloma, including trial design, primary endpoints, reported statistical analyses, safety, and interpretation.
- CASTAn independent statistical analysis of CAST, the phase 3 Cardiac Arrhythmia Suppression Trial, covering its randomized double-masked prevention design, interventions, statistical framework, planned analysis considerations, and limitations of the registry record.
- Caverject User Study: Complete Statistical AnalysisIndependent statistical analysis of Caverject User Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01008605).
- CDI-SCOPEIndependent statistical analysis of A Multi-center, Single-arm Trial Exploring the Safety and Clinical Effectiveness of RBX2660 Administered by Colonoscopy to Adults With Recurrent Clostridioides Difficile Infection: primary endpoint results, effect estimate with…
- CELESTIALIndependent statistical analysis of the phase 3 CELESTIAL trial of cabozantinib versus placebo in hepatocellular carcinoma after prior sorafenib, including overall survival, progression-free survival, objective response, trial design, and statistical methodology.
- CERTAIN-2Independent statistical analysis of A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus Infection: primary endpoint results, effect estimate with confidence…
- Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis: Complete Statistical AnalysisIndependent statistical analysis of Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01087762).
- Cetrorelix Pamoate in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH): Complete Statistical AnalysisIndependent statistical analysis of Cetrorelix Pamoate in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00663858).
- Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer: Complete Statistical AnalysisIndependent statistical analysis of Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- CHAARTEDIndependent statistical analysis of CHAARTED (NCT00309985), a randomized phase 3 trial of androgen-deprivation therapy with or without docetaxel in metastatic hormone-sensitive prostate cancer.
- ChangHER-SCIndependent statistical analysis of Phase III to Evaluate Patient´s Preference of Subcutaneous Trastuzumab vs Intravenous in HER2+ Advanced Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- CHARISMAIndependent statistical analysis of CHARISMA, a randomized phase 3 trial of clopidogrel in patients with arteriosclerosis, including its design, primary endpoint, planned time-to-event analysis, and statistical interpretation.
- CHARM-AddedIndependent statistical analysis of CHARM-Added, a randomized phase 3 trial evaluating candesartan cilexetil versus placebo in patients with congestive heart failure.
- CHARM-AlternativeIndependent statistical analysis of CHARM-Alternative, a phase 3 randomized trial evaluating candesartan versus placebo in congestive heart failure. Includes trial design, endpoints, planned statistical methods, and interpretation.
- CHARM-PreservedIndependent statistical analysis of CHARM-Preserved, the randomized phase 3 trial evaluating candesartan cilexetil versus placebo in congestive heart failure. Includes trial design, endpoints, statistical methodology, and interpretation.
- CheckMate 8HWIndependent statistical analysis of A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC):…
- CheckMate 914Independent statistical analysis of A Study Comparing Nivolumab, Nivolumab in Combination With Ipilimumab and Placebo in Participants With Localized Kidney Cancer Who Underwent Surgery to Remove Part of a Kidney: primary endpoint…
- CheckMate 915Independent statistical analysis of CheckMate 915, a randomized phase 3 trial of nivolumab plus ipilimumab versus nivolumab alone after complete surgical removal of stage IIIb/c/d or stage IV melanoma.